Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

20150924 smb cristal therapeutics jeroen tonnaer


Published on

Presentation Science Meets Business @ Health Valley From Molecule to Business 20150924

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

20150924 smb cristal therapeutics jeroen tonnaer

  1. 1. From Molecule to Business Health Valley/SMB September 24, 2015 Nijmegen CriPec® Nanomedicines for Superior Therapeutic Performance Dr. Jeroen Tonnaer, CBO
  2. 2. 2 Introduction • Pharmaceutical company developing nanomedicines • Founded in April 2011 • Located in Maastricht, The Netherlands • Headcount: 10 fte • Private - VC funded: 2
  3. 3. 3 CriPec® Nanomedicines Improved efficacy and tolerability CriPec® improves the therapeutic profile of drugs as a result of: • Extended systemic circulation • Improved disposition over the body • Active or passive targeting to tissue, cellular and molecular targets • Tuneable and timely release 3
  4. 4. CriPec® polymer drug linker entrapment of drug, so inactive release native drug & degradation NP coupling of drug drug linker CriPec® polymer incl. linker drug lactic acid Unique CriPec® Platform Transiently stable nanomedicines 4 PATENT PROTECTED BY 5 PATENT FAMILIES
  5. 5. range of therapeutic agents (small molecules - peptides) biodegradable and safe fragments multiple administration routes controllable size from 30 nm up to 100 nm X surface functionalisation for cellular and molecular targeting ease of manufacturing customised drug release Unique Features of CriPec® Highly flexible nanomedicinal platform 5
  6. 6. Therapeutic effect CriPec® Docetaxel Breast xenograft model 6 s.c. MDA-MB-231 xenografts in nude mice (n=8±SD) 0 14 28 42 56 0 250 500 750 1000 1250 1500 single dose vehicle Taxotere 60 mg/kg CriPec docetaxel 60 mg/kg time (days) tumourvolume(mm3 ) s.c. MDA-MB-231 xenografts in nude mice (n=10±SD) 0 14 28 42 56 0 250 500 750 1000 1250 1500 1750 2000 vehicle Taxotere 30 mg/kg CriPec docetaxel 125 mg/kg single dose time (days) tumourvolume(mm3 )
  7. 7. Unique Opportunity • CriPec® is unique and competitive nanotechnology platform that enables development of multiple (targeted) products • CriPec® boosts efficacy and improves tolerability • Applicable in disease areas with high unmet medical need • First product started clinical development July 2015 • Attractive co-development potential • CriPec® platform & products are protected by 5 patent families 7
  8. 8. Value Drivers • Clinical - Clinical phase I: safety of CriPec® docetaxel and PK profile - Clinical phase IIa/IIb: efficacy of CriPec® docetaxel • Platform - In house PoC for CriPec® peptide, CriVac® antigen, and CriPec® active targeting (ATN) - A commercial viable, robust and generic cGMP-manufacturing process • Business - Successful feasibility studies for partners - Successful (license) partnerships (full (co-)development programs) 8
  9. 9. Pipeline 9 indication discovery PoC preclinical phase I phase IIa Proprietary programs CriPec® docetaxel solid tumours CriPec® dexamethasone inflammatory CriPec® active targeting solid tumours CriPec® oligonucleotides various Collaborative programs CriPec® peptides solid tumours CriVac® antigens solid tumours achieved ongoing
  10. 10. General BD&L Considerations DO: • Understand the candidate licensee’s strategy and needs - Unlikely our opportunity will move the company’s strategy - Look for gaps we can fill - Ask for specific guidance on what the company is looking for • Appeal to licensee’s core values, for example: - Cutting-edge science - Novel medicines that make a difference • Demonstrate how our offering fits into their pipeline or research framework 10
  11. 11. General BD&L Considerations DON’T: • Forget that there is a fundamental difference between research (which advances technology without being constrained by business requirements) and product development (which must satisfy customer needs with safe, proven therapies that are competitive and cost-effective) • Expect to successfully license technology with no proven customer or market fit 11
  12. 12. CriPec® Docetaxel BD&L Considerations • Concept of disruptive vs. incremental innovation • Understanding stakeholders’ innovation preference • Multinationals • Regional players (e.g. Asian Pharma) • Adopters (e.g. innovative generics manufacturers) • Drafting CriPec® docetaxel licensing strategy • Analysis of market gaps in oncology • New application areas for CriPec® docetaxel • Competitive landscape (USPs vs. taxotere & NM competition) • Stakeholders landscape • Valuation of CriPec® docetaxel • Outline licensing deal 12
  13. 13.